Hydroxypropyl‐β‐cyclodextrin hybrid nanogels as nano‐drug delivery carriers to enhance the solubility of dexibuprofen: Characterization, in vitro release, and acute oral toxicity studies.

Abstract: The purpose of this study was to develop and characterize hydroxypropyl‐β‐cyclodextrin (HPβCD) hybrid nanogels for solubility enhancement of lipophilic drug, dexibuprofen. HPβCD hybrid nanogels were designed by chemical cross‐linking of hydroxypropyl‐β‐cyclodextrin with 2‐acrylamido‐2‐methyl propane sulfonic acid (AMPS) via free radical polymerization. Loading efficiency, solubilization, zetasizer, FESEM Fourier transform infrared (FTIR), differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), powder X‐ray diffraction (PXRD), and in vitro drug release analysis were performed for characterization of hybrid nanogels. Efficient solubilization of dexibuprofen has been observed by HPβCD hybrid nanogels. FTIR, TGA, and DSC studies confirmed the formation of new hybrid nanogels and complexation of dexibuprofen with nanogels. XRD analysis revealed loss of dexibuprofen crystallinity in hybrid nanogels. Highly porous and amorphous nanogels showed a significant dexibuprofen release in aqueous medium. In toxicity studies, no significant changes in behavioral, physiological, biochemical, or histopathological parameters of animals endorsed that developed formulations are nontoxic and biocompatible. [ABSTRACT FROM AUTHOR]